Page 14 - பல்கலைக்கழகம் மருத்துவமனைகள் கிளீவ்லேண்ட் மருத்துவ மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பல்கலைக்கழகம் மருத்துவமனைகள் கிளீவ்லேண்ட் மருத்துவ மையம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பல்கலைக்கழகம் மருத்துவமனைகள் கிளீவ்லேண்ட் மருத்துவ மையம் Today - Breaking & Trending Today

Opinion | Telemedicine Is a Tool. Not a Replacement for Your Doctor's Touch.


Dr. Rosenthal, a contributing opinion writer, was an emergency room physician before becoming a journalist.
Earlier in the pandemic it was vital to see doctors over platforms like Zoom or FaceTime when in-person appointments posed risks of coronavirus exposure. Insurers were forced — often for the first time — to reimburse for all sorts of virtual medical visits and generally at the same price as in-person consultations.
By April 2020, one national study found, telemedicine visits already accounted for 13 percent of all medical claims compared with 0.15 percent a year earlier. And Covid hadn’t seriously hit much of the country yet. By May, for example, Johns Hopkins’s neurology department was conducting 95 percent of patient visits virtually. There had been just 10 such visits weekly the year before. ....

Johns Hopkin , Peter Pronovost , University Hospitals Cleveland Medical Center , பீட்டர் ப்ரொநோவோஸ்ட் , பல்கலைக்கழகம் மருத்துவமனைகள் கிளீவ்லேண்ட் மருத்துவ மையம் ,

ADC Therapeutics gets the nod from the FDA for its ADC


The US Food and Drug Administration (FDA) has approved ADC Therapeutics’ ZYNLONTA as a third-line therapy for patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
The CD19-targeted antibody drug conjugate (ADC) was granted accelerated approval by the US regulator based on overall response rate.
The approval also covers patients with DLBCL arising from low grade lymphoma and high-grade B-cell lymphoma.
“This is the first ever approval of a PBD based ADC,”​ noted Chris Martin, CEO, ADC Therapeutics, on a conference call about the regulatory development and commercial launch.
The Lausanne, Switzerland based biotech is now entering ....

Jennifer Herron , Paolof Caimi , Chris Martin , Case Comprehensive Cancer Center , Case Western Reserve University , University Hospitals Cleveland Medical Center , Markets Amp Regulations , Antibody Drug Conjugates , ஜெனிபர் ஹெரான் , கிறிஸ் மார்டின் , வழக்கு விரிவான புற்றுநோய் மையம் , வழக்கு மேற்கு இருப்பு பல்கலைக்கழகம் , பல்கலைக்கழகம் மருத்துவமனைகள் கிளீவ்லேண்ட் மருத்துவ மையம் , சந்தைகள் ஆம்ப் ஒழுங்குமுறைகள் ,